At Clayton plant, Grifols begins phase 3 testing for COVID-19 treatment
Date Published:
RESEARCH TRIANGLE PARK — Grifols, a global biotherapeutics company, has begun Phase 3 clinical trials in patients with COVID-19 with…
Grifols
As FDA authorizes plasma to combat COVID-19, Clayton plant working on possible treatment
Date Published:
CLAYTON – President Donald Trump announced emergency authorization to treat COVID-19 patients with convalescent plasma — a move he called…
How North Carolina beat big competition to win a $350 million investment
Date Published:
Called by the code-name “Project 625,” Grifols Therapeutics pitted North Carolina against the Lone Star State as it considered where…
Grifols begins manufacturing potential COVID-19 treatment at Clayton facility
Date Published:
CLAYTON – Grifols, a global biotherapeutics company with major operations in North Carolina, has begun producing the first specific COVID-19…
Grifols to invest $356M for new facility in Clayton, adding hundreds of jobs
Date Published:
CLAYTON — Grifols, a global biotherapeutics company with already more than 2,000 employees in North Carolina, is investing $351.6 million…
Diagnosed with COVID-19 and recovered? Here’s a chance to contribute to pandemic fight
Date Published:
RESEARCH TRIANGLE PARK – If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find…
Grifols begins accepting plasma from recovered COVID-19 patients
Date Published:
Grifols is now accepting plasma from volunteer donors who have recovered from the COVID-19 virus at its Raleigh area locations.…
Why a JoCo facility could soon be mass producing a COVID-19 treatment
Date Published:
While the world battles the COVID-19 pandemic, a drugmaker with a massive presence in North Carolina is looking for recovered…
Grifols pursues development of coronavirus treatment based on blood plasma
Date Published:
RESEARCH TRIANGLE PARK – Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and…